$BEAT

Director-linked entity buys 31,250 HeartBeam (NASDAQ: BEAT) shares

An entity associated with HeartBeam (NASDAQ: BEAT) director Michael R. Jaff, Open Book Healthcare, purchased 31,250 shares of common stock at $0.80 per share on April 16, 2026. This transaction was part of HeartBeam's underwritten public offering of 12,500,000 shares, which closed on the same day. Following the purchase, 31,250 shares are now indirectly held for Michael R. Jaff.

Original reporting
Published Apr 17, 2026, 12:57 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 17, 2026, 1:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$BEAT
Bullish
medium confidence
Mentioned
$BEAT
alphai data visualization · based on Stock Titan
Decision brief

The 30-second read

$BEATBullishMed
01

Why it matters

The insider purchase during the offering suggests confidence, but also raises questions about dilution effects and market perception.

02

Market read

The insider activity is relevant for short-term traders and investors focused on HeartBeam, with limited impact on broader markets.

03

What to watch

Market conditions, overall company fundamentals, and upcoming catalysts should be considered before acting on this news.

Timing: Immediate, as the transaction occurred on April 16, 2026.

Background

HeartBeam recently conducted an underwritten public offering of 12.5 million shares, which closed on April 16, 2026.

Company-level read

Ticker impact

$BEATBullishMedium confidence
Context

High relevance due to insider purchase and recent offering.

Expected impact

Moderate upward price movement expected in the short term, contingent on broader market conditions.

Evidence & confidence

The insider purchase suggests confidence, but the overall impact is tempered by the fact that the purchase was part of a public offering, which can dilute existing shares.

Market effects

Potential positive sentiment for the life sciences sector, especially biotech companies with recent insider activity.

Limited regional impact; primarily relevant to U.S. markets.

Minimal direct relevance; company-specific event.

Counterpoint

The insider purchase may be strategic to support the stock price amid dilution concerns; it does not necessarily indicate strong future performance.

Key entities

  • HeartBeam Inc.

    A developer of cardiac diagnostic and monitoring solutions.

  • Michael R. Jaff

    A director of HeartBeam, associated with the insider purchase.

Related articles

$ACIMed

Albertsons recalls ready-to-eat items in multiple states amid salmonella-linked jalapeño investigation

Albertsons Companies said it is voluntarily recalling four ready-to-eat products containing jalapeños supplied by Taylor Farms, including items sold at Randalls in Texas. The recall followed a supplier recall tied to an ongoing federal investigation and an FDA probe of a Salmonella Javiana outbreak. FDA reported 345 illnesses in 27 states, 36 hospitalizations, no deaths.

$CMGMed

Salmonella outbreak from Mexican jalapeños reported in 27 U.S. states

U.S. health authorities are investigating a Salmonella outbreak linked to Mexican jalapeño peppers. The CDC and FDA say 345 people are ill across 27 states, with 36 hospitalizations and no deaths. The supplier, Coast Citrus Distributors, recalled peppers sent to restaurants including Chipotle and QDOBA. Chipotle removed jalapeños from some outlets and shares fell over 8% on Aug. 4.

$RKLBMedAI 8/10

Rocket Lab Just Unveiled a Game-Changing Technology Worth Watching

Rocket Lab (RKLB) said it won a $397 million U.S. Space Force contract to develop, launch, and operate multiple Flatellites for the SB-AMTI program. Flatellites are slimmer, stackable satellites intended to increase deployments per launch and integrate with Rocket Lab’s Neutron rocket. The article cites analyst forecasts for revenue rising from $602M (2025) to $1.7B (2028).